Distinct Requirements for Optimal Growth and In Vitro Expansion of Human CD34(+)CD38(-) Bone Marrow Long-term Culture-initiating Cells (LTC-IC), Extended LTC-IC, and Murine in Vivo Long-term Reconstituting Stem Cells
Overview
Affiliations
Recently, primitive human bone marrow (BM) progenitors supporting hematopoiesis in extended (>60 days) long-term BM cultures were identified. Such extended long-term culture-initiating cells (ELTC-IC) are of the CD34(+)CD38(-) phenotype, are quiescent, and are difficult to recruit into proliferation, implicating ELTC-IC as the most primitive human progenitor cells detectable in vitro. However, it remains to be established whether ELTC-IC can proliferate and potentially expand in response to early acting cytokines. Here, CD34(+)CD38(-) BM ELTC-IC (12-week) were efficiently recruited into proliferation and expanded in vitro in response to early acting cytokines, but conditions for expansion of ELTC-IC activity were distinct from those of traditional (5-week) LTC-IC and murine long-term repopulating cells. Whereas c-kit ligand (KL), interleukin-3 (IL-3), and IL-6 promoted proliferation and maintenance or expansion of murine long-term reconstituting activity and human LTC-IC, they dramatically depleted ELTC-IC activity. In contrast, KL, flt3 ligand (FL), and megakaryocyte growth and development factor (MGDF) (and KL + FL + IL-3) expanded murine long-term reconstituting activity as well as human LTC-IC and ELTC-IC. Expansion of LTC-IC was most optimal after 7 days of culture, whereas optimal expansion of ELTC-IC activity required 12 days, most likely reflecting the delayed recruitment of quiescent CD34(+)CD38(-) progenitors. The need for high concentrations of KL, FL, and MGDF (250 ng/mL each) and serum-free conditions was more critical for expansion of ELTC-IC than of LTC-IC. The distinct requirements for expansion of ELTC-IC activity when compared with traditional LTC-IC suggest that the ELTC-IC could prove more reliable as a predictor for true human stem cell activity after in vitro stem cell manipulation.
Vasalou V, Kotidis E, Tatsis D, Boulogeorgou K, Grivas I, Koliakos G J Clin Med. 2023; 12(17).
PMID: 37685753 PMC: 10488606. DOI: 10.3390/jcm12175683.
Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy.
Laje P, Shang D, Cao W, Niiya M, Endo M, Radu A Blood. 2009; 113(10):2172-80.
PMID: 19141866 PMC: 2652365. DOI: 10.1182/blood-2008-08-173021.
Towards predictive models of stem cell fate.
Viswanathan S, Zandstra P Cytotechnology. 2008; 41(2-3):75-92.
PMID: 19002945 PMC: 3466685. DOI: 10.1023/A:1024866504538.
Delaney C, Varnum-Finney B, Aoyama K, Brashem-Stein C, Bernstein I Blood. 2005; 106(8):2693-9.
PMID: 15976178 PMC: 1366491. DOI: 10.1182/blood-2005-03-1131.
Ostby I, Rusten L, Kvalheim G, Grottum P J Math Biol. 2003; 47(2):101-36.
PMID: 12883857 DOI: 10.1007/s00285-003-0198-6.